From Google Scholar+ [to 20 July 2013]

From Google Scholar & other sources: Selected Journal Articles, Dissertations, Theses, Commentary

Receipt of human papillomavirus vaccine among privately insured adult women in a US Midwestern Health Maintenance Organization
EO Kharbanda, E Parker, JD Nordin, B Hedblom… – Preventive Medicine, 2013
Objectives To describe human papillomavirus (HPV) vaccine coverage among adult privately insured women including variation in coverage by race/ethnicity. Methods This cross-sectional, observational study included women 18–26 years of age with continuous …

O10. 2 A Community-Randomised Phase IV Human Papillomavirus (HPV) Vaccination Trial of Vaccination Strategy
J Paavonen – Sexually Transmitted Infections, 2013
… Abstract. High-risk human papillomavirus (hrHPV) is the 2nd leading cause of cancer in women Bivalent Cervarix™ vaccine is highly efficacious against hrHPVs and associated precancers. Mathematical models disagree about the best vaccination strategy. …

Novel HIV vaccine strategies: overview and perspective
Yehuda Z. Cohen, Center for Virus and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, USA; Raphael Dolin, Beth Israel Deaconess Medical Center, Boston, USA
Published online before print July 15, 2013, doi: 10.1177/2051013613494535 Therapeutic Advances in Vaccines July 15, 2013 2051013613494535
A human immunodeficiency virus (HIV) vaccine remains a central component in the quest to control the worldwide epidemic. To examine the status of the development of HIV vaccines, we review the results of the efficacy trials carried out to date and the immunologic principles that guided them. Four vaccine concepts have been evaluated in HIV-1 vaccine efficacy trials, and the results of these trials have provided significant information for future vaccine development. While one of these trials demonstrated that a safe and effective HIV vaccine is possible, many questions remain regarding the basis for the observed protection and the most efficient way to stimulate it. Novel HIV vaccine strategies including induction of highly potent broadly neutralizing antibodies, use of novel homologous and heterologous vector systems, and vectored immunoprophylaxis seek to expand and build upon the knowledge gained from these trials.

Immunogenicity of Quadrivalent Human Papillomavirus Vaccine in Organ Transplant Recipients
D Kumar, ER Unger, G Panicker, P Medvedev… – American Journal of Transplantation…, 2013
Abstract Solid organ transplant recipients are at risk of morbidity from human papillomavirus
(HPV)-related diseases. Quadrivalent HPV vaccine is recommended for post- transplant patients but there are no data on vaccine immunogenicity. We determined the …